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1. Introduction
All chemical transformations pass through an unstable structure called the transition state,
which is poised between the chemical structures of the substrates and products. The transi‐
tion states for chemical reactions are proposed to have lifetimes near 10-13 sec, the time for a
single bond vibration. Thus, the transition state is the critical configuration of a reaction sys‐
tem situated at the highest point of the most favorable reaction path on the potential-energy
surface, with its characteristics governing the dynamic behavior of reacting systems deci‐
sively. It is used primarily to understand qualitatively how chemical reactions take place.
Yet transition state structure is crucial to understanding enzymatic catalysis, because enzymes
function by lowering activation energy. Linus Pauling coiled an accepted view, that incredible
catalytic rate enhancements caused by enzyme is governed by tight binding to the unstable
transition state structure in 1948. Because reaction rate is proportional to the fraction of the re‐
actant in the transition state complex, the enzyme was proposed to increase the concentration
of these reactive species. This proposal was further formalized by Wolfenden (1972) and cow‐
orkers, who hypothesized that the rate increase imposed by enzymes is proportional to the af‐
finity of the enzyme to the transition state structure relative to the Michaelis complex.
Transition state structures of enzymatic targets for cancer, autoimmunity, malaria and bacteri‐
al antibiotics have been explored by the systematic application of kinetic isotope effects and
computational chemistry. Today the combination of experimental and computational access to
transition-state information permits the design of transition-state analogs as powerful enzy‐
matic inhibitors and exploration of protein features linked to transition-state structure.
Molecular electrostatic potential maps of transition states serve as blueprints to guide syn‐
thesis of transition state analogue inhibitors of chosen enzymes. Substances, that ideally
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mimic geometric and electrostatic features of a transition state (or other intermediates of
high energy) are considered as excellent enzyme inhibitors (Fig.1). They bind up to 108 times
tighter than substrate. Thus, the goal of transition-state analogs design is to create stable
chemical structures with van der Waals geometry and molecular electrostatic potential sur‐
faces as close as possible to those of the transition state.
Although some reviews on the subject have been published, this concept has not been re‐
viewed in detail [Wolfenden, 1999; Robertson, 2005; Schramm, 2005; Schramm, 2007; Dyba‐
ła-Defratyka et al. 2008; Schramm, 2011]. In this review the current trends, alongside with
appropriate case studies in designing of such inhibitors will be presented.
2. Choice of the target enzyme
The sequencing of the human genome has promised a revolution in medicine. The genome
encodes 20,000- 25,000 human genes, and thousands more proteins as a result of alternative
gene splicing. Many of these hold the keys to treating disease, especially numerous enzymes of
undefined so far physiologic functions [Gonzaga-Jagureui et al., 2012]. Out of 1200 registered
drugs over 300 act as enzyme inhibitors. Most of them are simple analogs of substrates of cer‐
tain enzymatic reaction. Analogy to transition state as a mean to obtain effective inhibitors
emerged in 1970s [Lienhard, 1973]. Through the 1970s and 1980s, most of the known examples
were natural products [Wolfenden, 1976]. The situation has changed in 1990s when synthetic
inhibitors became the predominate examples of transition-state inhibitors. In 1995, there were
transition-state analogues for at least 130 enzymes [Radzicka & Wolfenden, 1995].
Figure 1. Progress of the enzymatic reaction versus uncatalyzed one.
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The design of transition-state inhibitors is likely to become more frequent in the future,
alongside with the development of theory and technology for understanding enzyme transi‐
tion states. Today the sequence of information required to obtain transition state analog of
enzymatic reaction considers: choice of the suitable enzyme (most likely suited to kinetic
isotope effect measurement), selection of presumable mechanism(s) of catalyzed reaction,
measurement of kinetic isotope effects (KIE), computer-aided calculations matching the in‐
trinsic KIEs, construction of steric and electronic map of transition state and synthesis of sta‐
ble compound(s) matching this map [Schramm, 2007]. This procedure has been developed
gradually in parallel with the advances in KIE enzymology, computational chemistry, and
synthetic organic chemistry.
3. Determination of transition state architecture
At present, the most reliable method to determine three-dimensional architecture of transi‐
tion state is through the use of computational methods in conjunction with experimentally
measured kinetic isotope effect (KIE).
Isotopic substitution is a useful technique for probing reaction mechanisms. The change of
an isotope may affect the reaction rate in a number of ways, providing clues to the pathway
of the reaction. The advantage of isotopic substitution is that this is the least disturbing
structural change that can be effected in a molecule. Replacement of one isotope of the sub‐
strate by another at vicinity where bonds are being or re-hybridizing typically leads to a
change in the rate of the reaction. Thus, kinetic isotope effects measurements compare
kcat/KM values between isotope-labeled and natural abundance reactants. This provides in‐
formation about which bonds are broken or formed, and identifies changes in hybridization
that occur during the rate limiting step of a reaction. It is reached by conversion of atom-by-
atom KIE values to a specific static model with fixed bond angles and lengths by computa‐
tional matching to a quantum chemical model of the reaction of interest. Substrate,
intermediate and product geometries are located as the global minima. Transition-state
structures are located with a single imaginary frequency, characteristic of true potential en‐
ergy saddle points.
Such an analysis was performed recently for human thymidine phosphorylase, an enzyme
responsible for thymidine homeostasis, action of which promotes angiogenesis. Thus, inhib‐
itors of this enzyme might be considered as promising anticancer agents. Its transition state
was characterized using multiple kinetic isotope effect measurements applying isotopically
(3H, 14C and 15N) enriched thymidines, which were synthesized enzymatically [Schwartz et
al, 2010]. A transition state constrained to match the intrinsic KIEs was found using density
functional theory. In the proposed mechanism (Fig.2), departure of the thymine results in a
discrete ribocation intermediate. Thymine likely leaves deprotonated at N1 and undergoes
enzyme-catalyzed protonation before the next step. In the following step, the intermediate
undergoes nucleophilic attack from an activated water molecule to form the products. The
latter step is a reaction rate limiting step as determined by energetics of its transition state.
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The transition state model predicts that deoxyribose adopts a mild 3′-endo conformation
during nucleophilic capture (Fig. 2).
Such studies, although cumbersome and difficult, are being recently more and more popu‐
lar, as demonstrated by representative studies on Escherichia coli t-RNA-specific adenosine
deaminase [Luo & Schramm, 2008], glucoside hydrolases [Lee et al, 2004], human purine nu‐
cleoside phosphorylase [Murkin et al., 2007], Trypasnosoma cruzi trans-sialidase [Pierdomini‐
ci-Sottile et al., 2011], L-dopa decarboxylase [Lin & Gao, 2011] or cis-prenyltransferase [Hu et
al., 2010].
Figure 2. Mechanism of human thymidine phosphorylase catalyzed depirymidation of thymidine. The dash line repre‐
sents protonation step.
Computational chemistry provides techniques for the generation and exploration of the
multi-dimensional energy surfaces that govern chemical reactivity. Therefore, energy mini‐
ma and saddle points can be located and characterized. The pathways that interconnect
them can be determined. Thus, computational methods are increasingly at the forefront of
elucidating mechanisms of enzyme-catalyzed reactions, and shedding light on the determi‐
nants of specificity and efficiency of catalysis [Kollman et al., 2002; Parks et al., 2010; Wil‐
liams, 2010; Lonsdake et al., 2012].
At the beginning of a molecular modeling study choice upon the specific catalytic process to
model has to be undertaken. This decision may sound simple, but it includes the nontrivial
task of exhaustively searching the literature to determine what is already known about the
selected enzymatic system, either from experiments or from previous computational stud‐
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ies. Reaction mechanisms may have already been proposed in the literature, and thus pro‐
vide a logical starting point for modeling studies. The three-dimensional structure of the
enzyme, preferably with a bound substrate analog, reaction product or inhibitor, is among
the most critical sources of information. In practice, this usually means that a high-resolu‐
tion X-ray crystal structure of a reacting enzyme complex is required.
Molecular mechanics methods are important in simulations of enzymes, even though these
methods cannot model chemical reactions. For that molecular dynamics simulations, or
combination of molecular mechanics with quantum mechanical methods are commonly
used [Senn & Thiel, 2007; Hou & Cui, 2011; Kosugi & Hayashi, 2012; Londsdale et al., 2012].
Enzymes are large molecules consisting of thousands of atoms whereas the active site may
comprise only around 100 atoms. Since quantum chemical calculations are nowadays af‐
fordable only for up to a few hundred atoms (depending on the level of accuracy) the sys‐
tem is split into two regions: a small region encapsulating the reaction at the active site is
modeled with a quantum mechanical methods, while the rest of the enzyme alongside with
surrounding water is modeled using molecular mechanics (Fig. 3.)
Figure 3. Quantum mechanics/molecular mechanics calculation of an enzymatic reaction illustrated by cytochrome
P450 with bound cyclohexene [Lonsdake et al., 2010].
These calculations do not take in the consideration such an important factor as protein dy‐
namic. There is an agreement that fast (at nano- or picosecond scale) protein motions couple
directly to transition state formation in enzymatically catalyzed reactions and are an integral
part of the reaction coordinate. Slower protein dynamic motions also influence the heights
of barriers in enzymatic reactions, however detailed description of these effects require elab‐
oration of new computational methods [Saen-oon et al., 2008].
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4. Inhibitors of proteinases
First inhibitors being transition state analogs were designed for proteolytic enzymes. The
design was based on the resemblance of transition state of phosphonamidates and phos‐
phonic, phosphinic (Fig. 4) acids to the sp3 intermediate of the hydrolysis of peptide bond.
Because the lengths of oxygen-to-phosphorus and carbon-to-phosphorus bonds are signifi‐
cantly longer than the corresponding carbon-to-carbon and carbon-to-oxygen bonds, orga‐
nophosphorus fragment of the molecule might be considered as “swollen” tetrahedral
intermediate and thus can be treated similar to the transition state of this reaction.
Figure 4. Organophosphoprus compounds as transition state analog inhibitors of hydrolysis of peptide bonds.
Crystallography of enzyme-inhibitor complexes and molecular modeling studies had shown
that their potent inhibitory activities result from both: resemblance to the transition state
and strong electrostatic interactions between positively charged active-site metal ions (pre‐
dominantly zinc ions) and negatively charged phosphonic acid (or related) group [Mucha et
al., 2010; Mucha et al., 2011]. Although the phosphonate/phosphinate group is a rather weak
zinc complexing moiety, it offers other advantageous structural and electronic features [Col‐
linsova & Jiráček, 2000].
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Figure 5. Representative organophosphorus inhibitors of metalloproteinases.
Simple phosphonic acid analogs of amino acids and pseudopeptides, containing phosphi‐
nate moiety replacing scissile peptide bond, are acting via this mechanism and rank
amongst most potent inhibitors of metalloproteinases (Fig. 5). Inhibitors of neutral alanyl
(M1) and leucine (M17) aminopeptidases are among the most recognized and most inten‐
sively studied representatives of metal-containing exopeptidases of biomedical significance
[Lowther & Matthews, 2002; Grembecka et al., 2003; Vassiliou et. al. 2007]. Functions related
to tumorigenesis and invasion makes these enzymes molecular targets for the development
of potential anticancer drugs [Grembecka & Kafarski, 2001; Zhang & Xu, 2008; Fournié-Za‐
luski et al., 2009; Grzywa et al., 2010]. The recognized role of neutral aminopeptidase in the
pathogenesis of hypertension provides also an opportunity for regulating arterial blood
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pressure by their inhibitors [Banegas et al., 2006; Bodineau et al., 2008]. Additionally, two of
these pseudodipeptides appear to be excellent inhibitors when applied to Plasmodium falcipa‐
rum M1 and M17 aminopeptidases (Fig. 5), the protozoan counterparts of neutral and leu‐
cine aminopeptidases [Stack et al., 2007; Cunningham et al, 2008; McGowan et al., 2009;
McGowan et al., 2010]. They efficiently controlled the growth of P. falciparium in cultures,
including those of malaria cells lines resistant to chloroquine, and significantly reduced ma‐
laria infections in murine model (Plasmodium chabaudi) [Skinner-Adams et al., 2007]. These
findings positively validated P. falciparum M1 and M17 aminopeptidases as promising tar‐
gets for a novel treatment of malaria and identify new leads with anti-parasite potential
[Skinner-Adams et al., 2010; Thivierge et al., 2012].
The design and development of pseudopeptidic inhibitors of aminopeptidases are greatly
facilitated by two factors. First, the results of extensive structure-activity relationship stud‐
ies, available for a wide collection of fluorogenic substrates, have defined the requirements
of the S1 binding pockets of these enzymes [Drag & Salvesen, 2009; Drag et al., 2010; Gajda
et al., 2012; Poręba et al., 2011; Poręba 2012]. Second, computer-aided analysis of numerous
crystal structures available for leucine aminopeptidase has pointed to this enzyme as a pri‐
mary molecular target for extending and optimizing interactions within the S1’ pocket
[Grembecka et al., 2001; Jørgensen et al., 2002; Evdokimov et al., 2007; Khandelwal et al.,
2005; Khaliullin et al. 2010; Li et al., 2010].
Phosphinic pseudopeptides have also clearly revealed their potential for the regulation of
matrix metalloproteinases (MMPs, matrixins), zinc-dependent endopeptidases implicated in
the breakdown of the extracellular matrix [Yiotakis at al., 2004; Fisher & Mobashery, 2006].
Cleavage of the matrix component (collagen, lamanin, elastin, gelatin, etc.) is physiologically
essential for tissue remodeling processes such as morphogenesis, embryogenesis and repro‐
duction [Overall & Kleifield, 2006; Sang et. al., 2006]. Overexpression or inadequate level of
matrix metalloproteinases leads to pathological states such as osteoarthritis, rheumatoid ar‐
thritis and inflammation, but it is most associated with tumor growth, invasion, and meta‐
stasis. Angiogenetic process favored by these enzymes is essential for vascoularization and
growth of tumors. Thus, they were the first proteinase targets seriously considered for com‐
bating cancer. Despite that preliminary clinical/preclinical studies on MMP inhibition in tu‐
mor models brought positive results the outcome in the drug market has been so far
unsatisfactory. The spectacular failure of the last-step clinical trials is mainly due to a lack of
selectivity and serious side effects [Fisher & Mobashery, 2006]. The field is now resurging
with careful reinvestigation of the precise roles of each particular MMP member and a focus
on the development of selective inhibitors that fully discriminate between different mem‐
bers of the MMP family [Reiter et al., 2003; Matziari et al., 2007; Zucker & Cao, 2009; Devel
et al., 2010; Johnson et al., 2011]. Such selectivity had been reached by variation of peptide
scaffold by means of combinatorial pseudopeptide synthesis [Buchardt et al, 2000; Dive et
al., 2004] or by application of molecular modeling based on crystallographic studies of these
enzymes [Rao, 2005; Pirard, 2007; Verma & Hansch, 2007; Anzellotti & Farrell, 2008; Kalva et
al., 2012]. Representative selective inhibitors of this class are shown in Figure 6.
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Figure 6. Representative inhibitors selective against chosen matrix metalloproteinases.
Quite interesting approach is preparation of hybrid systems as this composed of a phosphi‐
nate transition state analogue that has been incorporated within a triple-helical peptide tem‐
plate. The template sequence was based on the α1(V)436-450 collagen region, which is
hydrolyzed at the Gly439-Val440 bond selectively by MMP-2 and MMP-9. In that manner high‐
ly selective inhibitor towards these two gelatinases was found [Lauer-Fields et al., 2007; La‐
uer-Fields et al., 2008].
Phosphinic transition state analog approach has been also recently applied for the design
and synthesis of novel potent inhibitors of other proteinases of medicinal importance. Thus,
inhibitors of angiotensin converting enzyme [Mores et al., 2008; Julien et al. 2010; Akif et al.,
2011] are potential drugs against hypertension, aspartyl aminopeptidase as antimalarial
agent [Teuscher et al., 2007], inhibitors of cathepsin C and renal dipeptidase may be consid‐
ered as potential anticancer agents [Gurulingappa et al., 2003: Mucha et al., 2004], inhibitors
of sortase, which is bacterial virulence protein [Kruger et al., 2004], whereas inhibition of py‐
roglutamyl peptidase II enhances the analeptic effect of thyrotropin [Matziari et al., 2008;
Lazcano et al. 2012].
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It is worth mentioning that Monopril®, the sodium salt of fosinopril [Fig. 7], the ester prodrug
of an angiotensin-converting enzyme (ACE) inhibitor fosinoprilat, is perhaps one of the
most effective implementation of transition state analogy in medicine [Powell et al., 1984].
Figure 7. Fosinopril and fosinoprilat.
Sulfonamides also mimic both shape and electronic environment of the transition state of
peptide bond hydrolysis. This approach was used for introduction of transition state inhibi‐
tors of HIV-protease, thermolysin and thrombine as well as haptens for generation of cata‐
lytic antibodies (Fig. 8) [Moree, et al., 1993; Moree, et al., 1995; Löwik et al., 2000; Liskamp &
Kruijzer, 2004; Turcotte et al., 2012]. Unfortunately most of them appeared to be ineffective.
This might be explained by non-typical bonding of potent inhibitor of this class with HIV
protease (Fig. 9). It appeared that sulfonamide moiety displaces water molecule from active
site and forms hydrogen bonds with two isoleucines, not as expected with catalytic aspartic
acids [Meanwell, 2011]. Thus, sulfonamide group does not act as transition state analogue.
Figure 8. Sufonamides as inhibitors of proteases.
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Begacestat (Fig. 8), an effective and potent inhibitor of γ-secretase is an exception here [May‐
er et al., 2008; Martone et al., 2009]. γ-Secretase catalyzes the final step in the generation of
amyloid β peptides from amyloid precursor protein. Amyloid β-peptides aggregate to form
neurotoxic oligomers, senile plaques, and congophilic angiopathy, some of the cardinal
pathologies associated with Alzheimer's disease. Begacestat appeared to be well tolerated in
mouse and dog toxicity studies and has been advanced to human clinical trials for the treat‐
ment of this neurological disease.
Figure 9. Mode of binding of sulfonamide HIV protease inhibitor.
Figure 10. Silenediols as proteinase inhibitors.
Dialkylsilanediols are tetrahedral functional groups that can mimic hydrated carbonyls and
thus might be also considered as „swollen“ intermediates of peptide bond hydrolysis. When
silanediols are embedded in a peptide-like structure, they are recognized by proteinases and
Transition State Analogues of Enzymatic Reaction as Potential Drugs
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act as hydrolytically stable entities. Thus, dialkylsilanol is an effective functional group for
the design of active site-directed protease inhibitors. This concept has been successfully test‐
ed by replacing the presumed tetrahedral carbon of thermolysin, HIV-protease and angio‐
tensin converting enzyme substrates with silanediol groups (Fig. 10), which resulted in
potent inhibitors of these enzymes [Juers et al., 2005; Sieburth & Chen, 2006; Bo et al., 2011;
Meanwell, 2011].
5. Hydroxyethylene intermediate analogs as inhibitors of proteases
Aspartic proteases generally bind 6-10 amino acid regions of their polypeptide substrates,
which are typically processed with the aid of two catalytic aspartic acid residues in the ac‐
tive site. Thus, there is usually considerable scope for building inhibitor specificity for a par‐
ticular aspartic protease by taking advantage of the collective interactions between a
putative inhibitor on both sides of its scissile amide bond, and a substantial portion of the
substrate-binding groove of the enzyme [Eder et al., 2007]. A very effective group of their
inhibitors are simple hydroxyethylene analogs of tetrahedral oxyanion intermediates of the
hydrolysis of peptide bonds. This approach is based on the structure of bestatin, a general
inhibitor of aminopeptidases and aspartyl proteinases isolated in 1976 from Streptomyces oli‐
voreticuli [Umezawa et al., 1976].
Today, HIV protease inhibitors constitute around 40% of available drugs against HIV. Near‐
ly all of them contain hydroxyethylene unit as transition state analog mimic, to mention on‐
ly Darunavir, Atazanavir, Fosamprenavir, Lopinavir (or Ritonavir) or the oldest one
Saquinavir (Fig. 11) [Brik & Wong, 2003; Pokorna et. al, 2009].
Availability of anti-HIV drugs enabled to introduce highly active antiretroviral therapy
(HAART), which resulted in dramatic decrease of the mortality and morbidity for a wide
variety of opportunistic viral, bacterial, fungal and parasitic infections among HIV-infected
individuals in economically developed countries [Andreoni & Perno, 2012]. Thus, the de‐
sign, development and clinical success of HIV protease inhibitors represent one of the most
remarkable achievements of molecular medicine. However, both the academias, as well as,
the industry need to continue in their effort to develop novel, more potent compounds. This
is mainly connected with HIV drug resistance, which in turn results from the high mutation
rate, caused by the lack of proofreading activity of the viral reverse transcriptase. The pat‐
tern of mutations associated with the viral resistance is extremely complex as shown in Fig‐
ure 12 [Pokorna et al., 2009]. Taken together, in spite of the indisputable success of the
HAART and benefit to patients, new approaches to the antiviral treatment are highly desira‐
ble [Clarke, 2007; Adachi et al., 2009; Pokorna et al., 2009; Alfonso & Mozote, 2011].
Quite interestingly, small modifications of core structure of the inhibitor results in minute
changes in inhibitor affinity to HIV protease as demonstrated in Figure 13 [Wu et al., 2008;
Mahalingham et al., 2010].
Studies conducted in order to evaluate the influence of these antiviral drugs on the develop‐
ment of parasites, which are known to co-infect HIV-positive individuals, surprisingly
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shown, that these drugs exhibit marked antiprotozoal activity. For example Saquinavir, Lo‐
pinavir, Indinavir directly inhibited the grown of Plasmodium falciparum in vitro at clinically
relevant concentrations. This findings suggest that some inhibitors of HIV protease are ac‐
tive against the most virulent human malaria parasite P. falciparum that is known to express
number of aspartic proteases (plasmepsins) [Skinner-Adams, et al., 2004; Alfonso & Mozote,
2011].
More than 25 million people are suffering from dementia, and the annual socioeconomic
worldwide costs have been estimated to exceed U.S. $200 billion. γ-Secretase, along with β -
secretase produces the amyloid β-protein of Alzheimer’s disease. Because of its key role in
the pathogenesis γ-secretase has been a prime target for drug discovery, and many inhibi‐
tors of this protease have been developed. These enzymes are also effectively inhibited by
Figure 11. Representative examples of clinical HIV protease drugs.
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Figure 12. Three-dimensional structure of HIV protease complexed with Darunavir. Mutations associated with resist‐
ance to clinically used inhibitors are depicted as balls.
Figure 13. Influence of linker length on activity of HIV protease inhibitors.
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peptidomimetics containing hydroxyethylene fragment replacing hydrolyzed peptide bond.
Only one drug (Semagacestat, Fig. 14) reached phase III clinical studies so far, however, un‐
covered evidence of cognitive worsening in treated patients compared with placebo led to
suspension of the trials in 2010. Anyway, design, synthesis and evaluation of new low-mo‐
lecular, nanomolar inhibitors of secretases, structure of which significantly drifted away
from peptidic transition state analogs (Fig. 14), is still challenging and brought new promis‐
ing results [Osterman et al., 2006; Wolfe, 2012]. Due to rapid technological progress in chem‐
istry, bioinformatics, structural biology and computer technology, computer-aided drug
design plays more and more important role in this respect [Avram et al., 2006; Fujimoto et
al., 2008; Xu et al., 2009; Al-Tel et al. 2011; Hamada et al., 2012].
Figure 14. Inhibitors of secretases.
Hypertension is a major risk factor for cardiovascular diseases such as stroke, myocardial
infarction, and heart failure, the leading causes of death in the Western world. Inhibitors of
the renin–angiotensin system have proven to be successful treatments for hypertension. As
renin specifically catalyses the rate limiting step of this system, it represents the optimal tar‐
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get for antihypertensive drugs. Aliskiren (Fig. 15), a promising drug lowering blood pres‐
sure in sodium-depleted marmosets and hypertensive human patients, was developed
using a combination of crystal structure analysis of renin–inhibitor complexes and computa‐
tional methods [Wood et al., 2003]. The therapy was introduced under the names Takturna
and Rasilez.
Figure 15. Aliskiren (left hand side) and its more potent analog.
Another possibility arose from use of fluoroketone derivatives. α-monofluoroketones are
approximately 50% hydrated, whereas the α,α-difluoroketones are 100% hydrated in aque‐
ous solutions (Fig. 16). The latter ones are obviously of choice because of their striking simi‐
larity to phosphinic inhibitors (two hydroxyls placed at terahedral atom). This approach is
applied very rarely but gave good inhibitors of fungal endothiapepsin [Tuan et al., 2007]
and matrix metalloprotease [Reiter et al., 2000] (Fig. 16).
Figure 16. Difluoroketones as transition state inhibitor.
6. Suicide substrates yielding transition state analogues
Peptide aldehydes and boronic acids are inhibitors of serine and threonine enzymes forming
both, hydrogen and covalent bonds in the enzyme active site. Tetrahedral adduct generated
from these compounds upon their action on enzymes bear a closer relationship to the struc‐
ture of the true intermediate and they may be considered as suicidal substrates. There is,
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however, an important difference between these two types of inhibitors. The boronic acid
derivative possesses a negative charge, whereas the hemiacetal adduct is neutral (Fig 17).
Figure 17. Suicidal substrates yielding transition state analogs
Hence, the peptidyl boronic acid adduct is a better transition state analog than the hemiace‐
tal formed from peptidic aldehyde [Polgár, 2005]. Aldehydes typically have a low preva‐
lence in drugs and drug candidates because of their potential chemical reactivity and
susceptibility to be engaged in a reduction/oxidation pathways in vivo. Therefore peptidyl
boronic acids are considered as far better drug candidates. Additionally slight changes in
pH can result in release of the inhibitor from the active site, which is profitous.
In 2003, bortezomib (Fig. 18), a first-in-class therapeutic, gained approval from the US Feder‐
al Drug Administration for the treatment of relapsed multiple myeloma and mantle cell
lymphoma. Approval in the UK, for multiple myeloma, followed in 2006. It possesses a
unique mode of action. Bortezomib acts as inhibitor of the 26S proteasome, the key regulator
of intracellular protein degradation, found in the nucleus and cytosol of all eukaryotic cells,
and forming part of the critical ubiquitin-proteasome system. This inhibition results in dis‐
ruption of homeostatic mechanisms within the cell that can lead to cell death.
Figure 18. Structure of bortezomib.
This finding initiated intensive researches on boronic inhibitors of serine and threonine pro‐
teases [Trippier & McGuigan, 2010]. For, example recently inhibitors of Lon proteases (bac‐
terial ATP-dependent protease conferring bacterial virulence) afforded interesting
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antibacterial agents [Frase and Lee, 2007], inhibitors of prostate-specific antigen for prostate
cancer imaging and therapy [LeBeau et al., 2008], antifungal inhibitors of kexin (regulatory
proteins from Candida) [Holyoak et al., 2004; Wheatley & Holyoak, 2007], inhibitor of HCV
NS3 protease as potential drug against hepatitis [Zhang et al., 2003; Venkatraman et al.,
2009], and anticancer and antibacterial inhibitors of proteasome [Hu et al., 2006]. Represen‐
tative examples of these inhibitors are shown in Figure 19.
Figure 19. Boronic acid based inhibitors.
Drug Discovery342
7. Other hydrolases
The data considering transition state analogue inhibitors of other hydrolases are practically
limited to inhibitors of β–lactamases, arginase and urease.
Antibiotic resistance, especially to widely prescribed β-lactam antibiotics, is a serious threat
to public health and is responsible for the increase in morbidity, mortality, and health care
costs related to the treatment of bacterial infections. In most cases emergence of antibiotic-
resistant bacteria is primarily driven by overuse of β-lactam antibiotics in food and agricul‐
tural products. The most prominent resistance mechanism is related to the expression of β-
lactamases, which hydrolyze β–lactam fragment of the drug molecule. In nature, four
classes of these enzymes exist. Three of them are serine-based, whereas fourth is zinc-de‐
pendent-hydrolase. To counteract β-lactamases, mechanism-based inhibitors were devel‐
oped to be administered in concert with β-lactam antibiotics. Presently, there are three
commercially available β-lactamase inhibitors (clavulanate, sulbactam, and tazobactam).
The new approach to obtain such inhibitors is combination of structure of potent β-lactam
antibiotics with a boronic [Thomson, et al., 2007; Eidam et al., 2010: Ke, et al., 2011; Chan, et
al., 2012] or phosphonic [Nukaga, et al., 2004] acid moieties with the goal of mimicking the
transition state and creating a high-affinity, reversible inhibitor that cannot be inactivated by
β-lactamases since they do not bear hydrolyzable β-lactam ring.
Figure 20. Transition state inhibitors of lactamases.
Arginase is a binuclear manganese metalloenzyme that serves as a therapeutic target for the
treatment of asthma, erectile dysfunction, and atherosclerosis. The hydrolysis of L-arginine
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to L-ornithine and urea (Fig. 21) is also the final cytosolic step of the urea cycle in mammali‐
an liver. S-(2-Boronoethyl)-L-cysteine is one of the most effective inhibitor of the enzyme
(Fig 21). The specificity determinants of amino acid recognition by arginase were identified
by X-Ray structure of human arginase I enzyme complexed with this inhibitor. These stud‐
ies undoubtedly shown that boronate adopts tetrahedral configuration [Cama et al., 2003 &
2003a; Shishova, et al., 2009]. Also aldehydes and sulfonamides similar to boronic acids ap‐
peared to be promising inhibitors of arginases [Shin et al., 2004].
Figure 21. Arginase catalyzed reaction and representative inhibitors of the enzyme.
Urease catalyzes hydrolysis of urea in the last step of organic nitrogen mineralization to give
ammonia and carbamate, which decomposes to give a second molecule of ammonia and bi‐
carbonate (Fig. 22). The hydrolysis of the reaction products induces an overall pH increase
that has negative implications both in human and animal health as well as in the ecosphere.
Urease is a virulence factor in infections of urinary (Proteus mirabilis, Ureaplasma urealyticum)
and gastrointestinal tracts (Helicobacter pylori), causing severe diseases such as peptic ulcers,
stomach cancer, and formation of urinary stones. The efficiency of soil nitrogen fertilization
with urea (the most used fertilizer worldwide) decreases due to ammonia volatilization and
root damage caused by soil pH increase. Thus, control of the activity of urease through the
use of inhibitors could counteract these negative effects [Kosikowska & Berlicki, 2011; Zam‐
belli et al., 2011]. Di- and triamides of phosphoric acid represent a group of urease inhibitors
with the highest activity. It is the direct consequence of their similarity to the tetrahedral
transition state of the enzymatic reaction of urea hydrolysis. Takeda Chemicals have patent‐
ed a large group of N-acyltriamido phosphates and found over 90 examples with nanomolar
activity against H. pylori urease, with flurofamide being the most effective (Fig. 22) [Kosi‐
kowska & Berlicki, 2011].
Recently design, synthesis, and evaluation of novel ogranophosphonate inhibitors of bacteri‐
al urease have been described as an attractive alternative to known phosphoramidates. On
the basis of the crystal structure of Bacillus pasteurii urease, several phosphinic acids and
their short peptides have been designed by using the computer-aided techniques. The step‐
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wise scheme of inhibitor design, shown in Figure 21, led to the synthesis of compounds with
low structural complexity, high hydrolytic stability and satisfactory biological activity
against various ureases, including cytoplasmic urease from pathogenic Proteus species [Vas‐
siliou et al., 2008; Berlicki et al., 2012; Vassiliou et al., 2012].
8. Peptide bond formation by ribosome
Ribosomes are molecular machines that synthesize proteins in the cell. Recent biochemical
analyses and high-resolution crystal structures of the bacterial ribosome have shown that
the active site for the formation of peptide bonds – the peptidyl-transferase center – is com‐
posed solely of rRNA. Thus, the ribosome is the largest known RNA catalyst and the only
natural ribozyme that has a synthetic activity. Peptide bond formation during ribosomal
protein synthesis involves an aminolysis reaction between the aminoacyl α-amino group
and the carbonyl ester of the growing peptide via a transition state with a developing nega‐
tive charge - the oxyanion. Therefore the observed intermediates and transition states are
similar to those observed in proteinases (Fig. 23). Structural and molecular dynamic studies
have suggested that the ribosome may stabilize the oxyanion in the transition state of pep‐
tide bond formation via a highly ordered water molecule [Rodnina et al., 2006; Carrasco et
al., 2011].
Figure 22. Urease hydrolysed reaction and evolution of the structure of its inhibitors.
To biochemically elucidate how the ribosome stabilizes the developing negative charge in
the transition state of peptide bond formation, a series of tetrahedral transition state mimics
were synthesized. Their relative binding affinities for the ribosomes also were measured
(Fig. 23). The obtained results confirmed high affinity of predicted mechanism of ribosome
action [Green & Lorsch, 2002; Weinger et al., 2004; Carrasco, et al., 2011].
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Figure 23. Transition state analog inhibitor of peptidyl transferase.
9. Enzymes forming amide and ester bonds via carboxylic-phosphate
anhydride
Activation of carboxylic group of amino acid by ATP-phosphorylation yielding mixed car‐
boxylic-phosphate anhydride is quite popular mechanism of synthesis of amide and ester
bonds.
D-Alanyl-D-alanine ligase is one of the key enzymes in peptidoglycan biosynthesis and is an
important target for antibacterial drugs. The enzyme catalyzes the condensation of two ala‐
nine molecules using ATP to produce D-Ala-D-Ala (Fig. 24), which is the terminal peptide
of a peptidoglycan monomer. Analogs of D-Ala-D-Ala, in which phosphonate or phosphi‐
nate moiety replaces peptide bond appear to be potent inhibitors. As determined by kinetic
[Ellsworth et al., 1996], X-Ray [Wu et al., 2008], and molecular modeling studies the inhibitor
behaves as substrate and reacts with ATP to produce ADP and a tight-binding phosphory‐
lated transition state analogue, which exerts inhibitory action against the enzyme (Fig. 24).
Thus, these compounds might be rather considered as suicide substrates.
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Figure 24. Mechanism of condensation of two molecules of D-Ala catalyzed by D-alanine-D-alanine ligase.
Similarly acting inhibitors have been found for glutamine synthetase (phosphinothricin and
methionine sulfoximine and their analogs) [Berlicki et al., 2005; Berlicki & Kafarski 2006;
Berlicki, 2008], γ-glutamylcysteine synthetase [Hibi et al., 2004], or penicillin binding pro‐
teins [Dzekieva et al., 2010; Dzekieva et al., 2012] (Fig. 25).
Figure 25. Inhibitors activated by ATP.
10. Nucleotide deaminases
Enzymes of the deaminase superfamily catalyze deamination of bases in nucleotides and
nucleic acids across in diverse biological contexts. Representatives that act on free nucleoti‐
des or bases are primarily involved in the salvage of pyrimidines and purines, or in their
catabolism in bacteria, eukaryotes and phages. Other members of the deaminase superfami‐
ly catalyze the in situ deamination of bases in both RNA and DNA. Such modifications play
a central role in RNA editing, which is critical for generating the appropriate anti-codon se‐
quences for decoding the genetic code, modification of the sequences of microRNA and oth‐
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er transcripts and alteration of the reading frames in mRNAs, defense against viruses via
hypermutation-based inactivation, and somatic hypermutation or class switching of antigen
receptor genes in vertebrates [Iyer et al., 2011].
Adenosine deaminase (ADA) is an enzyme present in all organisms and catalyzes the irre‐
versible deamination of adenosine and deoxyadenosine to inosine and deoxyinosine (Fig.
26). Both adenosine and deoxyadenosine are biologically active purines that can have a deep
impact on cellular physiology. For example it plays a vital role in regulating T-cell coactiva‐
tion. Deficiency of this enzyme in humans causes severe combined immunodeficiency. In‐
creased serum activity of this enzyme have been found in many infectious diseases caused
by microorganisms infecting the macrophages, in leprosy, brucellosis, HIV infections, viral
hepatitis, infectious mononucleosis, liver cirrhosis and tuberculosis. Its extended transition
state inhibitor – conformycin was isolated from Nocardia interforma and Streptomyces kanihar‐
aensis. Analogs of conformycin (Fig. 26) are proposed as an antineoplastic synergists and im‐
munosuppressants [Wolfenden, 2003].
The wide potential of these inhibitors may be illustrated by the fact that deaminoformycin
was recently applied to evaluate mechanisms responsible for lethality caused by genetic and
herbicide-based activity of adenosine deaminase [Sabina et al., 2007], as well as identifica‐
tion of highly selective inhibitor of purine salvage pathway in malaria parasites [Tyler et al.,
2007]. This is because of a unique feature of Plasmodium falciparum enzyme that catalyzes the
deamination of both adenosine and 5‘-methylthioadenosine.
Figure 26. Inhibitors of adenosine deaminase.
Guanine deaminase is an enzyme that hydrolyzes guanine to form xanthine that is unsuita‐
ble for DNA/RNA buildup. This enzyme has been found in normal or transformed human
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organs and sera. One of the approaches for antiviral/anticancer therapy is to design structur‐
al mimics of natural guanine as nucleic acid building blocks, with an anticipation that such
analogs would be incorporated into DNA/RNA of virus for cancer cells, interrupting their
normal replicative processes. Unfortunately these potent anticancer mimics are believed to
be substrates for the enzyme guanine deaminase, which converts them into their respective
inactive forms. A potent inhibitor would restore the original potency of these anticancer
compounds. Such an activity was determined for azepinomycin [Isshiki et al., 1987] and its
analog designed as transition state of this reaction (Fig. 27) [Chakraborty et al., 2011].
Figure 27. Apizenomycin as a template for guanine deaminase inhibitor.
11. Glycosidases and related enzymes
Glycoside hydrolases, the enzymes catalyzing hydrolysis of the glycosidic bond in di-, oligo-
and polysaccharides, and glycoconjugates, are ubiquitous in Nature and fundamental to ex‐
istence. The extreme stability of the glycosidic bond caused that they have evolved into
highly proficient catalysts, with an estimated 1017 fold rate enhancement over the uncata‐
lysed reaction. Such rate enhancements mean that enzymes bind the substrate at the transi‐
tion state with extraordinary affinity [Gloster & Davies, 2010].
In the most cases of glycoside hydrolysis, the short-lived transition state possesses substan‐
tial oxocarbenium character (Fig. 27) resembling classical SN1 reaction intermediate. Under
these conditions the anomeric carbon possesses trigonal character, which causes sp2 hybridi‐
sation predominantly along the bond between the anomeric carbon and endocyclic oxygen
and significant relative positive charge accumulation on the pyranose ring [Lee et al., 2004;
Biarnés et al., 2011; Davies at al., 2012].
The quest for potent and selective inhibitors of glycosidases is extremely active at present.
This results from the involvement of glycosidases in lysosomal storage disorders, cancer, vi‐
ral infections, diabetes and many others. Consequently a plethora of glycosidase inhibitors
have been already synthesized and evaluated. The number of them is continually growing.
It is outside the scope of this chapter to mention all of them in detail. One of the most ap‐
pealing ways to design a transition state analog would be to incorporate both the features of
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geometry and charge present at the transition state. Distortion of the ring to generate com‐
pounds which may resemble the geometry of the transition state can be done by introducing
a double bond in the pseudo-glycoside ring itself, whereas introduction of the charge might
be done by application of sulfonium or ammonium ions [Rempel & Withers, 2008; Gloster &
Davies, 2010; Sumida et al., 2012].
Figure 28. Mechanism of β-glucosidase action [after Vasella et al., 2002].
Some representatives, which fulfills these requirements are: salicinol, one of the active prin‐
ciples in the aqueous extracts of Salacia reticulata that is traditionally used in Sri Lanka and
India for the treatment of diabetes [Ghavami et al., 2001] and its structurally variable ana‐
logues [Liu et al., 2006; Bhat et al., 2007; Mohan & Pinto, 2008].
Figure 29. Salicinol and its analogs.
Sialic acids play an important role in a variety of biological processes. They are usually at‐
tached to the terminal positions of glycoproteins, glycolipids and oligosaccharides. From
more than 100 different sialic acids, N-acetylneuraminic acid (NeuAc) is the most abundant
one. Sialidases or neuraminidases are a family of exo-glycoside hydrolases that catalyze the
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cleavage of terminal sialic acid residues from sialylated oligosaccharides, glycoproteins, and
glycolipids. Aberrant expression of different human sialidases was found to associate with
various pathological conditions, including lysosomal storage diseases such as sialidosis and
galactosialidosis. Non-specific transition-state analog of sialidase, 2-deoxy-2,3-dehydro-N -
acetylneuraminic acid (DANA, Fig. 30) is a good starting point for the synthesis of specific
inhibitors of human enzymes [Streicher & Busse, 2006; Li et al., 2011].
Figure 30. Chemical structures of neuraminidaze inhibitors.
Influenza viruses, in particular those of type A that can infect animals and humans, continue
to represent a major threat to public health and animal health worldwide. The social and
economic burden associated with a pandemic is substantial. Two viral surface glycoproteins,
the sialoside-hydrolysing neuraminidase and the sialic acid-binding hemagglutinin, have
become important targets for such approach. Most likely, the function of flu virus neurami‐
nidase is to remove sialic acid receptors for the virus from the host cells, and also, perhaps
more importantly, from the newly formed virus particles themselves [Nelson & Holmes,
2007; Medina & Garcia-Sastre, 2011]. Three inhibitors of neuraminidase have been success‐
fully introduced as anti-influenza drugs, all of them being transition state analog inhibitors.
They were designed by systematic reduction of DANA structure using crystallographic data
and computer-aided methods [Wei, et al., 2006]. Relenza (zanamivir) was the first inhibitor
to be synthesized which specifically inhibited neuraminidases of both Type A and Type B
influenza viruses and is effective in controlling influenza infections. In people is given as a
powder by oral inhalation [Palese et al., 1974]. Interestingly, it is weaker inhibitor of neura‐
midase than DANA, however, DANA inhibited influenza virus replication in tissue culture
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but failed to prevent disease in flu-infected animals. In order to produce a neuraminidase
inhibitor, which was orally bioavailable and which was taken orally in capsules or as a sus‐
pension, Tamiflu (oseltavimir) was developed in 1997 [Kim et al.]. Third drug, which has
been authorized for the emergency use of treatment of certain hospitalized patients with
known or suspected 2009 H1N1 influenza, is permavir [Chand, et al., 2005]. Structures of
these drugs are presented in Figure 30.
All three drugs soon became lead structures for the design and preparation of new, presum‐
ably more effective ones. Syntheses and eveluation of phosphinic analogs and significantly
simplified analogs of permavir (Fig. 31) have been recently described [Kati et al., 2001; Bian‐
co et al., 2005; Shie et al., 2007; Udommaneethanakit et al., 2009].
Figure 31. Second generation of influenza neuraminidase inhibitors.
Modified phosphonic analogs of oseltamivir were used to functionalize gold nanoparticles
and were found to bind strongly and selectively to all seasonal and pandemic influenza vi‐
rus strains, and thus could serve as prototypes for novel virus sensors. This may be helpul in
fast influenza diagnosis [Stanley et al., 2012].
12. Transition state analogues of nucleic acids metabolism
N-Ribosyltransferases are a general class of enzymes that catalyze nucleophilic displacement
reactions by migration of the cationic ribooxacarbenium carbon from the fixed purine to
phosphate and water nucleophiles, respectively. Two major classes of these enzymes are hy‐
drolases and phosphorylases. Hydrolases, which release the heterocycle to generate a free
sugar ribosyl unit, include enzymes for DNA repair, RNA depurinations by plant toxins,
and purine and pyrimidine nucleoside and nucleotide metabolism. Phosphorylases, which
transfer ribosyl groups to phosphate, are also involved in the pathway for nucleoside sal‐
vage. Genetic defects in this pathway prevent normal purine catabolism in humans.
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The focus on transition states for a family of N-ribosyltransferases roots from physiologic
importance of these enzymes. Similarly as in the case of glycosidases, most sugar transferas‐
es form transition states with cationic charge at the anomeric carbon. The geometry is al‐
tered at this center from sp3 (tetrahedral geometry) in the reactant sugar to sp2 (trigonal
planargeometry) at the transition state (Fig. 32) [Schramm, 2002; Murkin et al., 2007; Silva et
al., 2011].
Figure 32. Course of reaction catalyzed by N-ribosyltransferases.
Newborns with a genetic deficiency of purine nucleoside phosphorylase are normal, but ex‐
hibit a specific T-cell immunodeficiency during the first years of development. All other cell
and organ systems remain functional. Human purine nucleoside phosphorylase degrades
deoxyguanosine, and apoptosis of T-cells occurs as a consequence of the accumulation of
deoxyguanosine in the circulation. Thus, control of T-cell proliferation is desirable in T-cell
cancers, autoimmune diseases, and tissue transplant rejection. The search for powerful in‐
hibitors of these enzymes as anti-T-cell agents has culminated in the discovery of immucil‐
lins. The atomic replacements between inosine and immunocilin H make an insignificant
change in atomic size, but a dramatic change in the molecular electrostatic potential surface
(Fig. 33). Thus, analysis of the molecular electrostatic potential surface similarity between
transition state and immucilin confirmed utility of this simple approach in helping to design
effective inhibitor [Schramm, 2002; Schramm, 2007].
Evolution of immucilin structure, performed using standard structural analogy techniques,
enabled to obtain new inhibitors of purine nucleotide phosphorylase of nano- to picomolar
affinities to the enzyme (Fig. 34) [Evans et al., 2008; Edwards et al., 2009; Ho et al. 2010; Rej‐
man et al., 2012].
Plasmodium parasites (causative agents of malaria) are purine auxotrophs and require pre‐
formed purine bases for synthesis of nucleotides, cofactors, and nucleic acids. The purine
phosphoribosyltransferases catalyze transfer the 5-phosphoribosyl group from 5-phospho-
α-D-ribofuranosyl-1-pyrophosphate to salvage hypoxanthine, guanine, or xanthine to form
intracellular nucleosides. Purine salvage in Plasmodium falciparum uses hypoxanthine formed
in erythrocytes or in parasites by the sequential actions of adenosine deaminase and purine
nucleoside phosphorylase
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Figure 34. Effective inhibitors of purine nucleotide phosphorylase.
Therefore, effective inhibitors of both enzymes influence the life cycle of P. falciparum and
these pathways have been targets for antimalarials since the discovery that Plasmodium para‐
sites are purine auxotrophs.
Immunocillins HP and GP [Shi et al., 1999] and BCX4945 [Cassera et al., 2011] (Fig. 35) ap‐
pear to be effective inhibitors of phosphoribosyltransferases and are also able to influence
 
Figure 33. Molecular electrostatic potential surfaces for inosine, the transition state of purine nucleoside phosphory‐
lase and immucilin H.
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purine nucleoside phosphorylase, being dual inhibitor of the process. Especially the efficacy,
oral availability, chemical stability, unique mechanism of action and low toxicity of BCX4945
demonstrate potential for combination therapies with this novel antimalarial agent. Similar
studies have been also carried out for acyclic nucleoside phosphonates [Keough et al., 2009].
Figure 35. Antimalarial agents of dual inhibitory action.
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